Tolvaptan for the Management of Acute Decompensated Heart Failure in Patients With Advanced or Refractory Heart Failure

NCT02959411 Phase 4 TERMINATED

This study will clarify the clinical usefulness of Tolvaptan therapy in patients with complicated acute decompensated heart failure and hyponatremia (low blood sodium).

Details

Lead sponsor	University of Calgary
Phase	Phase 4
Status	TERMINATED
Enrolment	9
Start date	2016-10
Completion	2020-06-30

Conditions

• Heart Failure
• Hyponatremia

Interventions

• Tolvaptan
• Standard of care diuretic therapy

Primary outcomes

• Change in body weight — From randomization to 96 hours after randomization

Countries

Canada